{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Elanco Animal Health, Inc.
Elanco Animal Health Hits New 52-Week High of $22.86
Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.86 on October 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 23.74% over the past year, with a competitive P/E ratio of 14.00 and a manageable debt-to-equity ratio of 0.54.
Elanco Animal Health Hits New 52-Week High of $22.73
Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.73 on October 29, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 23.85% increase over the past year, showcasing significant recovery and growth within its market.
Elanco Animal Health Hits New 52-Week High of $22.25
Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.25 on October 24, 2025, reflecting strong performance with a 20.89% gain over the past year. The company has a market capitalization of USD 9,464 million and maintains a competitive P/E ratio and manageable debt levels.
Is Elanco Animal Health, Inc. overvalued or undervalued?
As of October 17, 2025, Elanco Animal Health, Inc. is considered overvalued with a valuation grade shift from very attractive to expensive, reflected by its lower P/E ratio compared to peers and poor long-term performance despite strong recent gains.
Elanco Animal Health Experiences Valuation Adjustment Amid Competitive Market Dynamics
Elanco Animal Health, Inc. has recently adjusted its valuation, reflecting changes in financial metrics within the Pharmaceuticals & Biotechnology sector. The company reports a P/E ratio of 14 and a price-to-book value of 1.09, with notable returns on capital and equity. Its year-to-date stock performance has significantly outpaced the S&P 500.
Is Elanco Animal Health, Inc. overvalued or undervalued?
As of October 17, 2025, Elanco Animal Health, Inc. is considered overvalued with a P/E ratio of 14 and an EV to EBITDA of 12.07, despite a strong year-to-date return of 76.88%, as its long-term performance has been poor with a 5-year return of -32.09%.
Is Elanco Animal Health, Inc. overvalued or undervalued?
As of October 17, 2025, Elanco Animal Health, Inc. is considered overvalued with a P/E ratio of 14 and a PEG ratio of 0.03, despite a strong year-to-date return of 76.88%, as its long-term performance has significantly lagged behind the S&P 500.
Elanco Animal Health Hits New 52-Week High at $21.76
Elanco Animal Health, Inc. achieved a new 52-week high of USD 21.76 on October 7, 2025, reflecting a strong upward trend from its low of USD 8.02. The company, with a market cap of approximately USD 9,464 million, operates in the Pharmaceuticals & Biotechnology sector and emphasizes growth.
Elanco Animal Health Hits New 52-Week High of $20.91
Elanco Animal Health, Inc. has achieved a new 52-week high of USD 20.91, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 14.04% gain over the past year and maintains a moderate debt-to-equity ratio, with a return on equity of 7.26%.
Elanco Animal Health Hits New 52-Week High at $20.19
Elanco Animal Health, Inc. achieved a new 52-week high of USD 20.19 on September 30, 2025, reflecting its performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 10.42% increase over the past year, with a market capitalization of USD 9,464 million and a P/E ratio of 14.00.
Elanco Animal Health Hits New 52-Week High at $19.70
Elanco Animal Health, Inc. achieved a new 52-week high of USD 19.70 on September 26, 2025, reflecting its performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 7.51% increase over the past year and maintains a manageable debt-to-equity ratio of 0.54.
Elanco Animal Health Hits New 52-Week High at $19.34
Elanco Animal Health, Inc. achieved a new 52-week high of USD 19.34 on September 22, 2025, reflecting its growth in the Pharmaceuticals & Biotechnology sector. The company has shown a 4.33% increase in stock performance over the past year, indicating steady progress and financial stability.
Is Elanco Animal Health, Inc. technically bullish or bearish?
As of September 9, 2025, Elanco Animal Health, Inc. shows a mildly bullish trend with strong weekly indicators, outperforming the S&P 500 recently, but underperforming over the longer term.
Is Elanco Animal Health, Inc. overvalued or undervalued?
As of August 11, 2025, Elanco Animal Health, Inc. is considered overvalued with a P/E ratio of 14 and an EV to EBITDA of 12.07, despite a strong year-to-date return of 57.72%, which lags behind the S&P 500's 70.41% return over the past three years.
Elanco Animal Health Hits New 52-Week High at $19.27
Elanco Animal Health, Inc. achieved a new 52-week high of USD 19.27, reflecting its growth in the Pharmaceuticals & Biotechnology industry. The company has shown a 4.71% performance increase over the past year, with a P/E ratio of 14.00 and a return on equity of 7.26%.
Is Elanco Animal Health, Inc. overvalued or undervalued?
As of May 7, 2025, Elanco Animal Health, Inc. is considered overvalued with a valuation grade shift from fair to expensive, reflected by a P/E ratio of 14, an EV to EBITDA of 12.07, and a ROE of 8.05%, while underperforming the S&P 500 with a stock return of -26.04% over the past year.
Is Elanco Animal Health, Inc. technically bullish or bearish?
As of June 20, 2025, the market trend is neutral with mixed signals: weekly indicators show bullish momentum while monthly indicators suggest bearish weakness, indicating caution without a clear trend.
Who are in the management team of Elanco Animal Health, Inc.?
As of March 2022, the management team of Elanco Animal Health, Inc. includes R. David Hoover (Independent Chairman), Jeffrey Simmons (President & CEO), and several Independent Directors: William Doyle, Kapila Anand, John Bilbrey, Scott Ferguson, and Art Garcia. They oversee the company's strategic direction and operations.
What does Elanco Animal Health, Inc. do?
Elanco Animal Health, Inc. develops and markets products for companion and food animals, with net sales of $1.193 billion and a market cap of approximately $6.76 billion. Key metrics include a P/E ratio of 14.00 and a return on equity of 8.05%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
